Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 374

1.

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.

Martin V, Chiriaco C, Modica C, Acquadro A, Cortese M, Galimi F, Perera T, Gammaitoni L, Aglietta M, Comoglio PM, Vigna E, Sangiolo D.

Br J Cancer. 2019 Mar;120(5):527-536. doi: 10.1038/s41416-018-0315-3. Epub 2019 Feb 6.

PMID:
30723303
2.

MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk.

Modica C, Tortarolo D, Comoglio PM, Basilico C, Vigna E.

Int J Mol Sci. 2018 Dec 7;19(12). pii: E3920. doi: 10.3390/ijms19123920. Review.

3.

Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation.

Virzì AR, Gentile A, Benvenuti S, Comoglio PM.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10058-10063. doi: 10.1073/pnas.1721147115. Epub 2018 Sep 17.

4.

Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies.

Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernández-Pérez D, Isella C, Granchi C, Minutolo F, Sottile A, Comoglio PM, Medico E, Pietrantonio F, Volante M, Pasini D, Chiarugi P, Giordano S, Corso S.

Cell Metab. 2018 Dec 4;28(6):848-865.e6. doi: 10.1016/j.cmet.2018.08.006. Epub 2018 Aug 30.

PMID:
30174307
5.

The expression of LINE1-MET chimeric transcript identifies a subgroup of aggressive breast cancers.

Miglio U, Berrino E, Panero M, Ferrero G, Coscujuela Tarrero L, Miano V, Dell'Aglio C, Sarotto I, Annaratone L, Marchiò C, Comoglio PM, De Bortoli M, Pasini B, Venesio T, Sapino A.

Int J Cancer. 2018 Dec 1;143(11):2838-2848. doi: 10.1002/ijc.31831. Epub 2018 Oct 4.

PMID:
30144023
6.

Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy.

Basilico C, Modica C, Maione F, Vigna E, Comoglio PM.

Int J Cancer. 2018 Apr 25. doi: 10.1002/ijc.31550. [Epub ahead of print] Erratum in: Int J Cancer. 2019 May 15;144(10):E5.

PMID:
29693242
7.

Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy.

Comoglio PM, Trusolino L, Boccaccio C.

Nat Rev Cancer. 2018 Jun;18(6):341-358. doi: 10.1038/s41568-018-0002-y. Review.

PMID:
29674709
8.

RON tyrosine kinase mutations in brain metastases from lung cancer.

Milan M, Benvenuti S, Balderacchi AM, Virzì AR, Gentile A, Senetta R, Cassoni P, Comoglio PM, Stella GM.

ERJ Open Res. 2018 Mar 6;4(1). pii: 00083-2017. doi: 10.1183/23120541.00083-2017. eCollection 2018 Jan.

9.

Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer.

Sponziello M, Benvenuti S, Gentile A, Pecce V, Rosignolo F, Virzì AR, Milan M, Comoglio PM, Londin E, Fortina P, Barnabei A, Appetecchia M, Marandino F, Russo D, Filetti S, Durante C, Verrienti A.

Hum Mutat. 2018 Mar;39(3):371-377. doi: 10.1002/humu.23378. Epub 2017 Dec 20.

PMID:
29219214
10.

MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.

Stella GM, Benvenuti S, Gentile A, Comoglio PM.

EBioMedicine. 2017 Oct;24:34-42. doi: 10.1016/j.ebiom.2017.09.025. Epub 2017 Sep 21. Review.

11.

A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem-Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy.

Luraghi P, Bigatto V, Cipriano E, Reato G, Orzan F, Sassi F, De Bacco F, Isella C, Bellomo SE, Medico E, Comoglio PM, Bertotti A, Trusolino L, Boccaccio C.

Clin Cancer Res. 2018 Feb 15;24(4):807-820. doi: 10.1158/1078-0432.CCR-17-2151. Epub 2017 Oct 3.

12.

Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor.

Orzan F, De Bacco F, Crisafulli G, Pellegatta S, Mussolin B, Siravegna G, D'Ambrosio A, Comoglio PM, Finocchiaro G, Boccaccio C.

Stem Cells. 2017 Nov;35(11):2218-2228. doi: 10.1002/stem.2703. Epub 2017 Sep 29.

13.

Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors.

Mira A, Morello V, Céspedes MV, Perera T, Comoglio PM, Mangues R, Michieli P.

Oncotarget. 2017 Jun 13;8(24):38193-38213. doi: 10.18632/oncotarget.16942.

14.

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, Antón A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M.

Lancet Oncol. 2016 Oct;17(10):1386-1395. doi: 10.1016/S1470-2045(16)30297-2. Epub 2016 Aug 27.

PMID:
27575023
15.

Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.

Apicella M, Migliore C, Capelôa T, Menegon S, Cargnelutti M, Degiuli M, Sapino A, Sottile A, Sarotto I, Casorzo L, Cassoni P, De Simone M, Comoglio PM, Marsoni S, Corso S, Giordano S.

Oncogene. 2017 Mar 2;36(9):1200-1210. doi: 10.1038/onc.2016.283. Epub 2016 Aug 15.

PMID:
27524418
16.

Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody.

Pupo E, Ducano N, Lupo B, Vigna E, Avanzato D, Perera T, Trusolino L, Lanzetti L, Comoglio PM.

Cancer Res. 2016 Sep 1;76(17):5019-29. doi: 10.1158/0008-5472.CAN-15-3107. Epub 2016 Jun 30.

17.

C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.

D'Amico L, Belisario D, Migliardi G, Grange C, Bussolati B, D'Amelio P, Perera T, Dalmasso E, Dalle Carbonare L, Godio L, Comoglio P, Trusolino L, Ferracini R, Roato I.

Oncotarget. 2016 Jul 19;7(29):45525-45537. doi: 10.18632/oncotarget.9997.

18.

MET inhibition overcomes radiation resistance of glioblastoma stem-like cells.

De Bacco F, D'Ambrosio A, Casanova E, Orzan F, Neggia R, Albano R, Verginelli F, Cominelli M, Poliani PL, Luraghi P, Reato G, Pellegatta S, Finocchiaro G, Perera T, Garibaldi E, Gabriele P, Comoglio PM, Boccaccio C.

EMBO Mol Med. 2016 May 2;8(5):550-68. doi: 10.15252/emmm.201505890. Print 2016 May.

19.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S.

Lancet Oncol. 2016 Jun;17(6):738-746. doi: 10.1016/S1470-2045(16)00150-9. Epub 2016 Apr 20. Erratum in: Lancet Oncol. 2016 Oct;17 (10 ):e420.

20.

Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

Cignetto S, Modica C, Chiriaco C, Fontani L, Milla P, Michieli P, Comoglio PM, Vigna E.

Mol Oncol. 2016 Jun;10(6):938-48. doi: 10.1016/j.molonc.2016.03.004. Epub 2016 Mar 28.

Supplemental Content

Loading ...
Support Center